Steve Schonfeld’s Amicus Therapeutics FOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-1,757,899
| Closed | -$25.4M | – | 2734 |
|
|
2026
Q1 | $25.4M | Buy |
1,757,899
+1,496,814
| +573% | +$21.5M | 0.18% | 104 |
|
|
2025
Q4 | $3.72M | Sell |
261,085
-1,102,980
| -81% | -$10.8M | 0.02% | 651 |
|
|
2025
Q3 | $10.7M | Buy |
1,364,065
+1,318,239
| +2,877% | +$9.38M | 0.06% | 335 |
|
|
2025
Q2 | $263K | Sell |
45,826
-263,311
| -85% | -$1.7M | ﹤0.01% | 1728 |
|
|
2025
Q1 | $2.52M | Buy |
309,137
+103,435
| +50% | +$957K | 0.02% | 853 |
|
|
2024
Q4 | $1.94M | Sell |
205,702
-97,156
| -32% | -$1.01M | 0.01% | 850 |
|
|
2024
Q3 | $3.23M | Buy |
302,858
+56,857
| +23% | +$619K | 0.02% | 695 |
|
|
2024
Q2 | $2.44M | Buy |
246,001
+168,025
| +215% | +$1.72M | 0.02% | 822 |
|
|
2024
Q1 | $919K | Buy |
+77,976
| New | +$997K | 0.01% | 1264 |
|
|
2022
Q3 | – | Sell |
-34,639
| Closed | -$372K | – | 3037 |
|
|
2022
Q2 | $372K | Sell |
34,639
-156,861
| -82% | -$1.29M | ﹤0.01% | 1533 |
|
|
2022
Q1 | $1.81M | Buy |
191,500
+143,200
| +296% | +$1.34M | 0.02% | 776 |
|
|
2021
Q4 | $558K | Buy |
+48,300
| New | +$538K | 0.01% | 1206 |
|
|
2021
Q2 | – | Sell |
-46,104
| Closed | -$455K | – | 2059 |
|
|
2021
Q1 | $455K | Sell |
46,104
-16,968
| -27% | -$263K | 0.01% | 1181 |
|
|
2020
Q4 | $1.46M | Sell |
63,072
-100,619
| -61% | -$2.06M | 0.02% | 689 |
|
|
2020
Q3 | $2.31M | Buy |
+163,691
| New | +$2.39M | 0.04% | 465 |
|
|
2020
Q1 | – | Sell |
-58,598
| Closed | -$571K | – | 1266 |
|
|
2019
Q4 | $571K | Sell |
58,598
-144,574
| -71% | -$1.32M | 0.01% | 700 |
|
|
2019
Q3 | $1.63M | Sell |
203,172
-269,828
| -57% | -$2.93M | 0.05% | 354 |
|
|
2019
Q2 | $5.9M | Buy |
473,000
+454,600
| +2,471% | +$5.77M | 0.21% | 120 |
|
|
2019
Q1 | $250K | Sell |
18,400
-52,600
| -74% | -$643K | 0.01% | 887 |
|
|
2018
Q4 | $680K | Buy |
+71,000
| New | +$780K | 0.03% | 570 |
|
|
2018
Q2 | – | Sell |
-198,597
| Closed | -$2.99M | – | 826 |
|
|
2018
Q1 | $2.99M | Buy |
198,597
+176,962
| +818% | +$2.69M | 0.22% | 133 |
|
|
2017
Q4 | $311K | Sell |
21,635
-59,957
| -73% | -$824K | 0.03% | 581 |
|
|
2017
Q3 | $1.23M | Buy |
+81,592
| New | +$1.08M | 0.11% | 231 |
|
|
2017
Q2 | – | Sell |
-27,611
| Closed | -$197K | – | 662 |
|
|
2017
Q1 | $197K | Buy |
+27,611
| New | +$175K | 0.02% | 549 |
|
|
2016
Q4 | – | Sell |
-24,754
| Closed | -$183K | – | 584 |
|
|
2016
Q3 | $183K | Buy |
+24,754
| New | +$167K | 0.03% | 371 |
|
|
2016
Q2 | – | Sell |
-11,022
| Closed | -$93K | – | 463 |
|
|
2016
Q1 | $93K | Buy |
+11,022
| New | +$78.1K | 0.04% | 288 |
|
Other funds holding FOLD
Steve Schonfeld's FOLD Position: Q2 2026 in Review
Steve Schonfeld sold out of Amicus Therapeutics (FOLD) in Q2 2026, closing a stake of 1,757,899 shares — an estimated $25.4M sold.
Steve Schonfeld first reported a position in FOLD in Q1 2016 and held it in 26 quarters. The position peaked at $25.4M in Q1 2026. 2 funds tracked by Wall St. Rank hold FOLD as of Q2 2026.
- Steve Schonfeld reported no remaining Amicus Therapeutics position as of Q2 2026 after selling out during the quarter.
- Steve Schonfeld sold 1,757,899 Amicus Therapeutics shares in Q2 2026, an estimated $25.4M.
- Steve Schonfeld first reported a position in Amicus Therapeutics in Q1 2016 and held it in 26 quarters.
- Steve Schonfeld's Amicus Therapeutics position peaked at $25.4M in Q1 2026.
- 2 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2026.
Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.